Chemotherapy for pancreatic cancer: the rise of multidrug regimens.

Malka, David;Borbath, Ivan;Conroy, Thierry
(2018) The Lancet. Gastroenterology & hepatology — Vol. 3, n° 10, p. 659-660 (2018)

Files

No attached file found for this publication.

Details

Authors
  • Malka, David
    Author
  • Borbath, IvanUCLouvain
    Author
  • Conroy, Thierry
    Author
Abstract
(en) The last decade has seen a humble king lose its throne. During 15 years of undivided rule, gemcitabine monotherapy, which is modestly active in the first-line treatment of metastatic pancreatic cancer, proved to be superior to all its challengers (largely gemcitabine plus another drug), until it was supplanted by a two-drug regimen (gemcitabine plus nab-paclitaxel), 1 and then a three-drug, gemcitabine-free, regimen (FOLFIRINOX [folinic acid, fluorouracil, irinotecan, and oxaliplatin]). 2 More recently, gemcitabine lost its crown in the adjuvant setting, again against a two-drug regimen (gemcitabine plus capecitabine) 3 and a three-drug regimen (modified FOLFIRINOX) [...]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Malka, D., Borbath, I., & Conroy, T. (2018). Chemotherapy for pancreatic cancer: the rise of multidrug regimens. The Lancet. Gastroenterology & hepatology, 3(10), 659-660. https://doi.org/10.1016/S2468-1253(18)30235-8 (Original work published 2018)